Jane Apperley

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Issues of imatinib and pregnancy outcome
    Jane Apperley
    Imperial College, Hammersmith Campus, London, England W12 0NN
    J Natl Compr Canc Netw 7:1050-8. 2009
  2. doi request reprint CML in pregnancy and childhood
    Jane Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, DuCane Road, London W120NN, UK
    Best Pract Res Clin Haematol 22:455-74. 2009
  3. pmc FISH mapping of Philadelphia negative BCR/ABL1 positive CML
    Anna Virgili
    Molecular Cytogenetics, Academic Haematology, Royal Free and UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK
    Mol Cytogenet 1:14. 2008
  4. ncbi request reprint Hematology. Imatinib--should we have more of a good thing?
    Jane F Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, DuCane Road, London, UK
    Nat Rev Clin Oncol 7:303-4. 2010
  5. doi request reprint Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
    Jane F Apperley
    Hammersmith Hospital, Imperial College School of Medicine, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 27:3472-9. 2009
  6. ncbi request reprint Part II: management of resistance to imatinib in chronic myeloid leukaemia
    Jane F Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
    Lancet Oncol 8:1116-28. 2007
  7. ncbi request reprint Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia
    Jane F Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
    Lancet Oncol 8:1018-29. 2007
  8. ncbi request reprint In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust and Imperial College London, London, United Kingdom
    Blood 111:2378-81. 2008
  9. doi request reprint Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:3358-63. 2008
  10. doi request reprint Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 120:291-4. 2012

Detail Information

Publications76

  1. ncbi request reprint Issues of imatinib and pregnancy outcome
    Jane Apperley
    Imperial College, Hammersmith Campus, London, England W12 0NN
    J Natl Compr Canc Netw 7:1050-8. 2009
    ..Alternative strategies for managing pregnancy in chronic myelogenous leukemia include one or both of regular leukapheresis and interferon-alpha. Pregnancy in advanced-phase disease presents particular problems...
  2. doi request reprint CML in pregnancy and childhood
    Jane Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, DuCane Road, London W120NN, UK
    Best Pract Res Clin Haematol 22:455-74. 2009
    ....
  3. pmc FISH mapping of Philadelphia negative BCR/ABL1 positive CML
    Anna Virgili
    Molecular Cytogenetics, Academic Haematology, Royal Free and UCL Medical School, Rowland Hill Street, London, NW3 2PF, UK
    Mol Cytogenet 1:14. 2008
    ..Here we present FISH mapping data of BCR and ABL1 flanking regions and associated chromosomal rearrangements in 9 Ph negative BCR/ABL1 positive CML patients plus the cell line CML-T1...
  4. ncbi request reprint Hematology. Imatinib--should we have more of a good thing?
    Jane F Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, DuCane Road, London, UK
    Nat Rev Clin Oncol 7:303-4. 2010
    ..A recent study compared the standard dose with higher doses in patients with newly diagnosed CML and found no difference in response rates at 12 months. But, is the devil in the detail?..
  5. doi request reprint Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
    Jane F Apperley
    Hammersmith Hospital, Imperial College School of Medicine, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 27:3472-9. 2009
    ..Pleural effusion occurred in 27% of patients (grade 3 to 4, 5%). CONCLUSION Dasatinib is effective in patients with CML-AP after imatinib treatment failure...
  6. ncbi request reprint Part II: management of resistance to imatinib in chronic myeloid leukaemia
    Jane F Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
    Lancet Oncol 8:1116-28. 2007
    ....
  7. ncbi request reprint Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia
    Jane F Apperley
    Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
    Lancet Oncol 8:1018-29. 2007
    ..This review is the first of two papers and discusses imatinib resistance and its potential causes. The second paper will focus on the assessment and subsequent management of patients with less than optimum responses to imatinib...
  8. ncbi request reprint In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust and Imperial College London, London, United Kingdom
    Blood 111:2378-81. 2008
    ....
  9. doi request reprint Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:3358-63. 2008
    ..Here, we report our experience in treating patients at a single institution in a setting where all events were recorded...
  10. doi request reprint Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 120:291-4. 2012
    ..2%, 0.92%, and 0.57% for complete cytogenetic response, 3 log and 4.5 log reductions in the transcript level, respectively. The study was registered at www.clinicaltrials.gov as #NCT01460693...
  11. doi request reprint BCR-ABL1 kinase domain mutations: methodology and clinical evaluation
    Mary Alikian
    Imperial Molecular Pathology Laboratory, Imperial College NHS Trust and Academic Science Centre, Hammersmith Hospital, London W12 OHS, United Kingdom
    Am J Hematol 87:298-304. 2012
    ..Advantages, disadvantages, interpretation of results, and their clinical applications are reviewed for each method...
  12. ncbi request reprint Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
    David Marin
    Department of Haematology, Hammersmith Hospital, W12 0NN, London, UK
    Lancet 362:617-9. 2003
    ..64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis...
  13. ncbi request reprint State-of-the-art in the treatment of chronic myeloid leukaemia
    Dragana Milojkovic
    Department of Haematology, The Hammersmith Hospital, London, UK
    Curr Opin Oncol 20:112-21. 2008
    ..To revise the current goals of therapy of chronic myeloid leukaemia and to incorporate the influence of the underlying chronic myeloid leukaemia biology on directing therapeutic management...
  14. pmc Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
    Fabrizio Vianello
    Department of Haematology, Kennedy Institute of Rheumatology, Imperial College, London, UK
    Haematologica 95:1081-9. 2010
    ..Mesenchymal stromal cells in the bone marrow may favor the persistence and progression of leukemia by preserving the proliferation and self-renewal capacities of the malignant progenitor cells...
  15. pmc The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
    Jamshid Sorouri Khorashad
    Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom
    Haematologica 94:861-4. 2009
    ....
  16. doi request reprint Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization
    Gareth Gerrard
    Imperial Molecular Pathology, Imperial College Academic Health Science Centre, London, United Kingdom
    Am J Hematol 87:717-20. 2012
    ..In an effort to accommodate the demands of increasing sample throughput and greater standardization, we adapted the current best-practice guidelines to encompass automation platforms and improved multiplex RT-qPCR technology...
  17. ncbi request reprint Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    David Marin
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, United Kingdom
    Cancer 103:1850-5. 2005
    ....
  18. ncbi request reprint Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)
    Marianna Politou
    Department of Haematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Br J Haematol 126:686-9. 2004
    ..Furthermore MIP-1alpha, bALP, and sRANKL/OPG may be useful tools for distinguishing between cases of MGUS and early myeloma...
  19. doi request reprint Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
    Aristeidis Chaidos
    Centre for Haematology, Faculty of Medicine, Imperial College London, London, United Kingdom
    Blood 119:5030-6. 2012
    ..In conclusion, higher doses of CD4(-) iNKT cells in PBSC grafts are associated with protection from aGVHD. This effect could be harnessed for prevention of aGVHD...
  20. doi request reprint European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    Blood 112:4437-44. 2008
    ..The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response."..
  21. ncbi request reprint Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, Du Cane Road, London, UK
    Br J Haematol 137:423-8. 2007
    ..There were no grade III or IV non-haematological adverse effects. Grade I fatigue, hypocalcaemia and fever were common side effects. No responses were demonstrated after 6 months on the combination...
  22. ncbi request reprint Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage
    Aristeidis Chaidos
    Department of Haematology, Hammersmith Hospital, DuCane Road, London W12 0NN, UK
    Best Pract Res Clin Haematol 20:125-54. 2007
    ..Where possible we have made some clear recommendations, but where evidence is less clear we have indicated the ongoing controversies...
  23. pmc Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
    Hugues de Lavallade
    Department of Haematology, Imperial College, Hammersmith Campus, 4th Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK
    Haematologica 96:307-14. 2011
    ..The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies...
  24. ncbi request reprint Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index
    Evangelos Terpos
    Department of Hematology, Faculty of Medicine Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, United Kingdom
    Blood 102:1064-9. 2003
    ....
  25. doi request reprint Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 28:2381-8. 2010
    ..There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence...
  26. pmc Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom
    Haematologica 95:224-31. 2010
    ..However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors...
  27. doi request reprint Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK
    Br J Haematol 145:373-5. 2009
    ..05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR...
  28. doi request reprint Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:4806-13. 2008
    ..Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear...
  29. ncbi request reprint The effects of imatinib on pregnancy outcome
    Seonaid M Pye
    Department of Haematology, Division of Investigative Science, Imperial College, London, United Kingdom
    Blood 111:5505-8. 2008
    ..It appears that although most pregnancies exposed to imatinib are likely to have a successful outcome, there remains a risk that exposure may result in serious fetal malformations...
  30. ncbi request reprint Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma
    Evangelos Terpos
    Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
    Br J Haematol 123:106-9. 2003
    ..021). This suggests that MIP-1alpha contributes to the pathogenesis of bone disease in MM and possibly in tumour growth, as reflected by its impact on survival...
  31. ncbi request reprint Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression
    Sarah Marktel
    Department of Hematology, Imperial College at Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
    Haematologica 88:260-7. 2003
    ....
  32. ncbi request reprint Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation
    Eduardo Olavarria
    Haematology Department, Hammersmith Hospital, London, England
    Blood 99:3861-2. 2002
    ..This case demonstrates that imatinib mesylate can be highly effective in the management of patients who have relapses after allograft for CML...
  33. doi request reprint Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia
    Paula Garland
    Department of Hematology, Imperial College London, Hammersmith Hospital, London, UK
    Future Oncol 7:201-18. 2011
    ....
  34. doi request reprint In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib
    Manuel Sobrinho-Simoes
    Department of Haematology, Imperial College London, London, United Kingdom
    Blood 116:1329-35. 2010
    ..Post-SCT, we found little evidence that the transcripts occasionally detected originate from the leukemic clone...
  35. doi request reprint Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 122:227-38. 2013
    ..These data indicate that TKIs, through off-target inhibition of kinases important in B-cell signaling, reduce memory B-cell frequencies and induce significant impairment of B-cell responses in CML. ..
  36. doi request reprint EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure
    Katayoun Rezvani
    Department of Hematology, Imperial College, Hammersmith Hospital, Du Cane Road, London, UK
    Biol Blood Marrow Transplant 18:235-40. 2012
    ..3% for risk score 4 (intermediate, n = 42), and only 10.4% for risk scores 5-7 (high, n = 57), P = .001. We propose that the EBMT risk score can identify patients most likely to benefit from a second transplantation...
  37. ncbi request reprint The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase
    Eduardo Olavarria
    Haematology Department, Hammersmith Hospital, ICSM, London, UK
    Br J Haematol 118:762-70. 2002
    ..01). Out of 155 patients refractory to IFN pre SCT, 70% achieved a cytogenetic response post SCT, which was complete or major in 31%. IFN refractory patients who sustained a CCR or MCR for 1-2 years after SCT had an excellent outcome...
  38. doi request reprint Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
    Blood 115:4018-20. 2010
    ..CML patients without comorbidities (HCT-CI score 0) with normal CRP levels (0-9 mg/L) may therefore be candidates for early allogeneic HCT after failing imatinib...
  39. ncbi request reprint Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia
    Jyoti Wadhwa
    Department of Haematology, Hammersmith Hospital and Faculty of Medicine, Imperial College at Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
    Blood 99:2304-9. 2002
    ..We conclude that survival after onset of BT has improved in recent years but is still unsatisfactory. We speculate that the combined use of STI571 with cytotoxic drugs may offer additional benefit...
  40. ncbi request reprint Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons
    Myrtle Y Gordon
    Leukaemia Research Fund Centre, Imperial College Faculty of Medicine, Hammersmith Campus, London, UK
    Br J Haematol 122:424-9. 2003
    ..01 and 0.03 respectively). We conclude that heterogeneity in the CML patient population is analogous to the constitutional diversity in normal subjects...
  41. ncbi request reprint Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
    Charles Crawley
    Department of Haematology, Addenbrooke s Hospital, Hills Road, Cambridge, UK
    Blood 109:3588-94. 2007
    ..0), and the conditioning intensity did not impact on overall survival or retain significance for PFS. These data suggest that there is a continuing need to investigate dose intensity in the conditioning for myeloma allografts...
  42. pmc Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
    Jaspal Kaeda
    Department of Haematology, Imperial College at Hammersmith Hospital, London, UK
    Blood 107:4171-6. 2006
    ....
  43. ncbi request reprint Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma
    Evangelos Terpos
    Department of Haematology, Faculty of Medicine Imperial College London, Hammersmith Hospital, London, UK
    Eur J Haematol 75:376-83. 2005
    ..We also review all the available data in the literature for the optimal therapy for patients with isolated EM relapse...
  44. ncbi request reprint The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
    Mohamad Mohty
    Department of Hematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 110:380-3. 2007
    ..001). We conclude that BMI1 may be a biomarker for the intrinsic heterogeneity of CML, and its measurement at diagnosis can help predict overall survival and thus contribute to better therapeutic decisions...
  45. doi request reprint Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics
    Alistair G Reid
    Departments of Histopathology and Haematology, Hammersmith Hospital and Imperial College, London, UK
    Leuk Res 33:418-25. 2009
    ..Among myeloid-BC, CD34-negative cases were more often associated with trisomy-8, 17p-loss and numerical abnormalities, and the CD117-negative subset with additional copies of Ph (p<0.05)...
  46. ncbi request reprint Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
    Eduardo Olavarria
    Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
    Blood 110:4614-7. 2007
    ....
  47. doi request reprint Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements
    Valeria A S De Melo
    Department of Haematology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Cancer Genet Cytogenet 182:111-5. 2008
    ..1 and 22q11.2 chromosomal regions, regardless of the subsequent mechanism of chromosomal rearrangement...
  48. ncbi request reprint Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
    Jane F Apperley
    Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom
    N Engl J Med 347:481-7. 2002
    ..The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has impressive clinical efficacy in BCR-ABL-positive chronic myeloid leukemia...
  49. ncbi request reprint Clinical decisions for chronic myeloid leukemia in the imatinib era
    John M Goldman
    Department of Haematology, Imperial College London at Hammersmith Hospital, London, UK
    Semin Hematol 40:98-103; discussion 104-13. 2003
    ..It is likely that the role of imatinib, used alone or in combination with other agents, will be more clearly defined in the near future...
  50. ncbi request reprint Anti-angiogenic effect of bortezomib in patients with multiple myeloma
    Marianna Politou
    Department of Haematology, Faculty of Medicine Imperial College London, Hammersmith Hospital, London, UK
    Acta Haematol 114:170-3. 2005
  51. doi request reprint Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma
    Ian H Gabriel
    Department of Hematology, Imperial College, London, UK
    Blood 116:2033-9. 2010
    ....
  52. ncbi request reprint Personalized medical treatment strategies for patients with chronic myeloid leukemia
    Catherine Burton
    Imperial College School of Medicine, Department of Haematology, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK
    Expert Rev Anticancer Ther 5:343-53. 2005
    ....
  53. ncbi request reprint Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions
    Elisabet Nadal
    Department of Haematology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK
    Exp Hematol 32:218-23. 2004
    ..A total of 13 patients (8 with CML, 2 with AML, 2 with MM, 1 with NHL) relapsed after SCT and were treated with DLI. All had achieved only partial or no response after DLI. Recombinant IL-2 was thereafter administered...
  54. ncbi request reprint Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation
    Jolanta B Perz
    Department of Haematology, Hammersmith Hospital NHS Trust, Du Cane Road, W12 London, UK
    Leuk Res 31:1433-6. 2007
    ..1% in this cohort...
  55. ncbi request reprint Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
    Agnes S M Yong
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    Blood 107:205-12. 2006
    ....
  56. ncbi request reprint Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab
    Jolanta B Perz
    Department of Haematology, Hammersmith Hospital, Hammersmith Hospital NHS, Imperial College School of Medicine, London, United Kingdom
    Transpl Immunol 18:179-85. 2007
    ..In the poor risk group, HLA mismatches had a negative impact on survival (p=0.003) and progression free survival (p=0.009) contrary to CML-CP1 patients, in whom HLA mismatches at molecular or serological level did not have any impact...
  57. doi request reprint Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis
    Madhava Pai
    Department of Surgery, at Hammersmith Campus, Imperial College, London, United Kingdom
    Am J Gastroenterol 103:1952-8. 2008
    ..The aim of this study was to assess the safety and efficacy of administering autologous expanded mobilized adult progenitor CD34+ cells into the hepatic artery of ALC patients and the potential improvement in the liver function...
  58. ncbi request reprint Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
    Andreas Hochhaus
    III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Blood 109:2303-9. 2007
    ..This trial was registered at www.clinicaltrials.gov as CA180013...
  59. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    Philipp Le Coutre
    Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    Blood 111:1834-9. 2008
    ..In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228...
  60. ncbi request reprint Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment
    Beate Schultheis
    Blood 105:4893-4. 2005
  61. ncbi request reprint Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses
    David Marin
    Blood 102:2702-3; author reply 2703-4. 2003
  62. ncbi request reprint Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele
    Mona Anand
    Blood 108:2881-2. 2006
  63. ncbi request reprint Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
    Marianna David
    Department of Haematology, University of Pecs, Pecs, Hungary
    Blood 109:61-4. 2007
    ..Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion-positive, BCR-ABL-negative CMPDs...
  64. ncbi request reprint Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia
    Jolanta B Perz
    Haematologica 91:1145-6. 2006
    ..After a median of 203 days (range: 18-1419) overall and progression-free survival rates are 62% and 54%, respectively...
  65. ncbi request reprint ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
    Robert P Hasserjian
    Dept of Pathology, Baystate Medical Center, Springfield, MA 01199, USA
    Am J Clin Pathol 117:360-7. 2002
    ..Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis...
  66. ncbi request reprint Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
    Charles Crawley
    Clinical Haematology, Box 234, Addenbrookes Hospital, Cambridge, CB2 2QQ, United Kingdom
    Blood 105:4532-9. 2005
    ..While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit...
  67. ncbi request reprint Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)
    Tapani Ruutu
    Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
    Br J Haematol 118:1112-9. 2002
    ..TTP is a relatively frequent complication of allogeneic stem cell transplantation and it is associated with high mortality, though death is usually caused by multiple factors...
  68. ncbi request reprint No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib
    Marianna Politou
    Leuk Res 30:240-1. 2006
  69. ncbi request reprint The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations
    David Marin
    Haematologica 87:979-88. 2002
    ..It is also active in the management of patients in advanced phases of CML...
  70. ncbi request reprint Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
    Charles Crawley
    Clinical Haematology, Box 234, Addenbrookes Hospital, Cambridge, CB2 2QQ United Kingdom
    Blood 106:2969-76. 2005
    ..58). RIC allografts are feasible in CML in first or second CP. Since no other RIC regimen demonstrated superiority, Fd/Bu/ATG should be considered as baseline in future prospective trials...
  71. ncbi request reprint Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate
    David Marin
    Haematologica 88:227-9. 2003
  72. ncbi request reprint Stem cell transplantation for chronic myeloid leukemia in children
    Kate Cwynarski
    Paediatric and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation
    Blood 102:1224-31. 2003
    ..4; 95% CI, 1.36-4.3; P =.003) were significant. This is the first large series to show that SCT confers long-term LFS in most children with CML and helps assess alternative therapy, including tyrosine kinase inhibitors...
  73. ncbi request reprint Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
    Valeria A S De Melo
    Blood 110:3086-7. 2007
  74. doi request reprint Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
    Hugues de Lavallade
    Br J Haematol 141:745-7. 2008
  75. ncbi request reprint The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study
    Jennifer M Bird
    Bristol Haematology and Oncology Centre, Bristol, UK
    Br J Haematol 134:385-90. 2006
    ..Two of the four patients with amyloidosis have survived. HDT is feasible in these patients and results in 5-year survival in about one-third of patients...
  76. ncbi request reprint Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma
    Marleen H C Bakkus
    Laboratory of Haematology, Academic Hospital Vrije Universiteit Brussel, Laarbeeklaan 105, 1090 Brussels, Belgium
    Br J Haematol 126:665-74. 2004
    ..Quantitative molecular assessment thus may help to identify those patients who are in need of further treatment early after autologous transplantation...